Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase
- Nat Chem Biol. 2017 Aug;13(8):850-857. doi: 10.1038/nchembio.2386.
- 1. Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- 2. Howard Hughes Medical Institute, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- 3. Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- 4. Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
- 5. Laboratory of Epithelial Cancer Biology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
- 6. MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, UK.
- 7. Department of Molecular Machines and Signaling, Max Planck Institute of Biochemistry, Martinsried, Germany.
- 8. St. Jude Proteomics Facility, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
N-terminal acetylation is an abundant modification influencing protein functions. Because ∼80% of mammalian cytosolic proteins are N-terminally acetylated, this modification is potentially an untapped target for chemical control of their functions. Structural studies have revealed that, like lysine acetylation, N-terminal acetylation converts a positively charged amine into a hydrophobic handle that mediates protein interactions; hence, this modification may be a druggable target. We report the development of chemical probes targeting the N-terminal acetylation-dependent interaction between an E2 conjugating enzyme (UBE2M or UBC12) and DCN1 (DCUN1D1), a subunit of a multiprotein E3 Ligase for the ubiquitin-like protein NEDD8. The inhibitors are highly selective with respect to Other protein acetyl-amide-binding sites, inhibit NEDD8 ligation in vitro and in cells, and suppress anchorage-independent growth of a cell line with DCN1 amplification. Overall, our data demonstrate that N-terminal acetyl-dependent protein interactions are druggable targets and provide insights into targeting multiprotein E2-E3 ligases.